Emerging Growth Biotechnology Stocks
Cannabics Pharmaceuticals (CNBX) receives "Intention to Grant a European Patent"
Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: - Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Miami, FL – October 26, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging...
In the podcast, Mr. Teeple will discuss the current state of Can B Corp, along with its subsidiaries, new product launches, its FDA approved medical device and its strong medical advisory team.
Recently trading at around .70 per share, PetVivo Holdings, Inc. (OTCQB: PETV) just announced something interesting on Tuesday which brought a $1.40 share price and what could be the beginning of a strong accumulation of their stock.
Miami, FL –October 22, 2020, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for...
The writer also likes Facebook (NYSE: FB) citing the stock is cheap, being around 14% below its august highs. But with the largest hater of tech, (Elizabeth Warren) potentially coming into some great power if Biden should pull out a win, I would stay cautiously away from big tech as her plans could include break up’s of companies like FB.
Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.